首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1905867

感染疾病藥物市場規模、佔有率和成長分析（按類型、治療方法和地區分類）—2026-2033年產業預測

Infectious Disease Therapeutics Market Size, Share, and Growth Analysis, By Type (HIV, Hepatitis), By Treatment (Antibacterial, Antifungal Drugs), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，感染疾病治療市場規模將達到 1,249.3 億美元，到 2025 年將達到 1,302.1 億美元，到 2033 年將達到 1,813.9 億美元，在預測期（2026-2033 年）內，複合年成長率為 4.23%。

由病毒和細菌等多種病原體引起的感染疾病對全球醫療保健環境構成重大挑戰。儘管診斷技術、治療方法、衛生習慣、疫苗接種和抗菌療法的進步已降低了死亡率，但這些疾病的持續發生仍對全球健康狀況造成嚴重影響。由於感染率上升、早期診斷意識增強以及公共和私營部門研究經費的增加，感染疾病治療市場預計將顯著成長。然而，先進治療方法的高昂費用給患者帶來了沉重的經濟負擔，限制了市場成長。此外，人們對學名藥的偏好日益成長，也阻礙了品牌藥在該領域的廣泛應用。

感染疾病治療市場成長要素

感染疾病藥物市場的成長主要得益於旨在提高治療方案可及性和有效性的投資增加。提高大眾對現有治療方法和準確診斷重要性的認知也是推動市場成長的因素。此外，專注於開發創新藥物療法的臨床試驗研究激增，預計將進一步促進該市場的擴張。這些因素共同創造了一個充滿活力的環境，有利於感染疾病藥物領域的進步，最終改善患者的治療效果和提高治療能力。

感染疾病治療市場的限制

由於人們對各種疾病的現有治療方案缺乏了解，感染疾病治療市場面臨許多挑戰。這種認知不足可能導致醫療服務提供者和患者對治療方法的接受度較低。此外，發展中地區某些感染疾病的報銷政策限制進一步阻礙了市場擴張。這些因素共同構成了治療產業發展的障礙，因為它們導致有效治療方案的可近性和利用率較低，從而影響新興和成熟醫療體系中市場的整體發展。

感染疾病治療藥物市場趨勢

受印度、非洲和東南亞等發展中地區瘧疾發病率上升的推動，感染疾病治療市場正經歷顯著成長。這一成長促使領先的製藥公司和醫療機構加大研發投入，致力於開發創新治療方法和預防措施，以對抗感染疾病。公眾對公共衛生策略的日益重視以及對有效醫療解決方案的迫切需求，進一步推動了市場擴張。相關人員的合作，以及技術和診斷技術的進步，有望拓展治療選擇，最終為感染疾病防治創造一個穩健的市場環境。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2021-2023年營收年比比較

主要企業簡介

Gilead Sciences
GlaxoSmithKline（GSK）
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Pfizer Inc.
Novartis AG
Johnson & Johnson（Janssen Pharmaceuticals）
BioCryst Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
AbbVie Inc.
Sanofi
AstraZeneca
Bristol-Myers Squibb（BMS）
Moderna, Inc.
Regeneron Pharmaceuticals
Vertex Pharmaceuticals
Vir Biotechnology, Inc.
Eli Lilly and Company
Amgen Inc.

結論與建議

簡介目錄

Product Code: SQMIG35J2030

Infectious Disease Therapeutics Market size was valued at USD 124.93 Billion in 2024 and is poised to grow from USD 130.21 Billion in 2025 to USD 181.39 Billion by 2033, growing at a CAGR of 4.23% during the forecast period (2026-2033).

Infectious diseases pose a substantial challenge to the global healthcare landscape, driven by various agents like viruses and bacteria. Although advances in diagnostics, treatment, hygiene practices, vaccinations, and antimicrobial therapies have curbed mortality rates, the ongoing emergence of these diseases continues to significantly affect health outcomes worldwide. The market for infectious disease therapeutics is poised for considerable expansion, fueled by increasing incidences of infections, heightened awareness regarding early diagnosis, and enhanced research funding from both private and public sectors. Nonetheless, the high costs associated with advanced treatment options place a financial burden on patients, limiting market growth. Additionally, the rising preference for generic medications poses challenges for the uptake of branded therapeutics in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Infectious Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Infectious Disease Therapeutics Market Segments Analysis

Global Infectious Disease Therapeutics Market is segmented by type, treatment, end users and region. Based on type, the market is segmented into HIV, hepatitis, influenza, TB, malaria and HPV. Based on treatment, the market is segmented into antibacterial, antifungal drugs, antiviral drugs and others. Based on end users, the market is segmented into hospitals and clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Infectious Disease Therapeutics Market

The growth of the infectious disease therapeutics market is being driven by a rise in investment aimed at improving the accessibility and effectiveness of treatment options. Enhanced efforts to promote awareness regarding both the treatments available and the importance of accurate diagnosis are also contributing factors. Additionally, a surge in clinical trial research focused on developing innovative drug therapies is expected to further fuel this market's expansion. Collectively, these elements create a dynamic environment that supports advancements in the field of infectious disease therapeutics, ultimately improving patient outcomes and treatment capabilities.

Restraints in the Infectious Disease Therapeutics Market

The infectious disease therapeutics market faces challenges due to a lack of awareness regarding available treatment options for various disorders. This inadequate understanding can lead to low adoption rates of therapies among healthcare providers and patients. Additionally, the limited reimbursement policies for specific infectious diseases in developing regions further hinder market expansion. These factors collectively create obstacles to the growth of the therapeutics sector, as they contribute to decreased accessibility and utilization of effective treatment solutions, ultimately affecting the overall development of the market in both emerging and established healthcare systems.

Market Trends of the Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics market is witnessing significant traction, driven by the rising incidence of malaria in developing regions such as India, Africa, and Southeast Asia. This surge is accompanied by heightened research and development initiatives by leading pharmaceutical companies and healthcare organizations, focusing on innovative treatments and preventive measures against infectious diseases. The growing awareness of public health strategies and the urgent need for effective healthcare solutions further bolster market expansion. Collaboration among stakeholders, coupled with advancements in technology and diagnostics, is expected to enhance therapeutic options, ultimately shaping a robust market environment for infectious disease management.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies

Global Infectious Disease Therapeutics Market Size by Type & CAGR (2026-2033)

Market Overview
HIV
Hepatitis
Influenza
TB
Malaria
HPV

Global Infectious Disease Therapeutics Market Size by Treatment & CAGR (2026-2033)

Market Overview
Antibacterial
Antifungal Drugs
Antiviral Drugs
Others

Global Infectious Disease Therapeutics Market Size by End Users & CAGR (2026-2033)

Market Overview
Hospitals
Clinics

Global Infectious Disease Therapeutics Market Size & CAGR (2026-2033)

North America (Type, Treatment, End Users)
- USA
- Canada
Europe (Type, Treatment, End Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment, End Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment, End Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment, End Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (Janssen Pharmaceuticals)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioCryst Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (BMS)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vir Biotechnology, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments